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Corticosteroid and endocannabinoid actions converge on prefrontocortical circuits associated with
neuropsychiatric illnesses. Corticosteroids can also modulate forebrain synapses by using endocanna-
binoid effector systems. Here, we determined whether corticosteroids can modulate transmitter release
directly in the frontal cortex and, in doing so, whether they affect presynaptic CB1 cannabinoid receptor-
(CB1R) mediated neuromodulation. By Western blotting of puriﬁed subcellular fractions of the rat frontal
cortex, we found glucocorticoid receptors (GcRs) and CB1Rs enriched in isolated frontocortical nerve
terminals (synaptosomes). CB1Rs were predominantly presynaptically located while GcRs showed
preference for the post-synaptic fraction. Additional confocal microscopy analysis of cortical and hip-
pocampal regions revealed vesicular GABA transporter-positive and vesicular glutamate transporter 1-
positive nerve terminals endowed with CB1R immunoreactivity, apposing GcR-positive post-synaptic
compartments. In functional transmitter release assay, corticosteroids, corticosterone (0.1e10 microM)
and dexamethasone (0.1e10 microM) did not signiﬁcantly affect the evoked release of [3H]GABA and
[14C]glutamate in superfused synaptosomes, isolated from both rats and mice. In contrast, the synthetic
cannabinoid, WIN55212-2 (1 microM) diminished the release of both [3H]GABA and [14C]glutamate,
evoked with various depolarization paradigms. This effect of WIN55212-2 was abolished by the CB1R
neutral antagonist, O-2050 (1 microM), and was absent in the CB1R KO mice. CB2R-selective agonists did
not affect the release of either neurotransmitter. The lack of robust presynaptic neuromodulation by
corticosteroids was unchanged upon either CB1R activation or genetic inactivation. Altogether,eduction of Animals in Research; 4-AP, 4-aminopyridine; ARRIVE, Animals in Research: Reporting In Vivo Experiments;
); corti, corticosterone; DAGLa, diacylglycerol lipase a; dexa, dexamethasone; DMSO, dimethylsulfoxide; DPM, disin-
ory Animal Science Associations; FR%, fractional release expressed as percentage; GPCR, G protein-coupled receptor;
-pituitary-adrenal; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; [3H]GABA, tritiated g-aminobutyric
epristone; PFC, prefrontal cortex; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; VGAT, ve-
ium channel(s); VGLUT1, vesicular glutamate transporter 1; WB, Western blotting; WIN, WIN55212-2.
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R.M. Bitencourt et al. / Neurochemistry International 90 (2015) 72e84 73corticosteroids are unlikely to exert direct non-genomic presynaptic neuromodulation in the frontal
cortex, but they may do so indirectly, via the stimulation of trans-synaptic endocannabinoid signaling.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Corticosteroids produce diverse responses in various classes of
neurons and astrocytes in the brain (Chaouloff and Groc, 2011; Jo€els
et al., 2012; Maggio and Segal, 2012; Yu et al., 2011). Alternative
splicing and post-translation modiﬁcations yield pharmacologi-
cally and structurally distinct subtypes of corticosteroid-sensing
mineralocorticoid and glucocorticoid receptors (McR and GcR).
These receptors can either mediate slow genomic responses when
located intracellularly or, they can directly control other receptors,
membrane conductance, release probability and synaptic plasticity
when inserted in the plasmalemma (Chaouloff and Groc, 2011;
Chen et al., 2012; Jo€els et al., 2012; Maggio and Segal, 2012; Tse
et al., 2011). Only a few of these responses were associated with
presynaptic loci, probably because non-genomic corticosteroid
modulation of ionic currents at the second to minute scale is less
typical (Jo€els et al., 2012; Zaki and Barrett-Jolley, 2002). The
particular mechanism(s) leading to rapid presynaptic neuro-
modulation by corticosteroids has not been fully elucidated, and
the underlying receptor has been ascribed either asMcR (Jo€els et al.,
2012; Karst et al., 2005; Maggio and Segal, 2012) or as GcR (Wang
and Wang, 2009).
Corticosteroids alone are often insufﬁcient to increase presyn-
aptic neurotransmitter release: acute stress rapidly raises the
readily releasable pool of glutamate in the rat (pre)frontal cortex,
and augments its depolarization-induced ex vivo release (Popoli
et al., 2011). However, corticosterone applied in vitro onto iso-
lated nerve terminals (synaptosomes) does not affect glutamate
release per se (Treccani et al., 2014).
In the prefrontal cortex (PFC), acute stimulation of glutamate
release by corticosteroids under stressful stimuli is among the ﬁrst
steps to terminate the stress response via a feed-back loop feeding
into the hypothalamo-pituitary-adrenal (HPA) axis (Herman et al.,
1996; Jo€els et al., 2012). Chronic stress, however, can impair the
delicate context of neuromodulation in the PFC, which can elicit
numerous neuropsychiatric illnesses (Opris and Casanova, 2014),
including impaired fear extinction (Bitencourt et al., 2013). We
recently found that GcRs rather than McRs facilitate prefrontal
cortex-dependent conditioned fear extinction by promoting
endocannabinoid signaling at CB1 cannabinoid receptors (CB1Rs)
(Bitencourt et al., 2014). Gi/o protein-coupled metabotropic CB1Rs
are expressed at high density in subsets of GABA-ergic in-
terneurons, while their expression at lower density is typical for
many pyramidal cells throughout the neocortex, with predominant
axonal (presynaptic) localization (Egertova and Elphick, 2000; Hill
et al., 2007; Marsicano and Lutz, 1999; Tsou et al., 1998). An addi-
tional CB1R paralogue, the CB2 cannabinoid receptor (CB2R) is
largely expressed peripherally with circumstantial evidence infer-
ring central roles (Zhang et al., 2015).
CB1Rs serve as downstream mediators of glucocorticoid action
in frontocortical and hippocampal areas. CB1Rs control the feed-
back loop along the HPA axis to terminate stress responses (Hill
et al., 2011; Hill and Tasker, 2012), as well as to facilitate the
extinction and impair the retrieval of aversive memories (Atsak
et al., 2012; Bitencourt et al., 2013, 2014; Hill et al., 2011;
Marsicano et al., 2002). Due to these important roles, endocanna-
binoids (endogenous CB1R agonists) have been implicated in thepathogenesis of chronic stress-related psychiatric illnesses
(Bitencourt et al., 2013; K€ofalvi and Fritzsche, 2008; Trezza and
Campolongo, 2013).
Prompted by the lack of conclusive evidence on a signaling
interplay between GcRs and CB1Rs, we aimed at mapping the acute
presynaptic effects of corticosteroids on the resting and
depolarization-evoked release of radiolabeled GABA and glutamate
in superfused synaptosomes of the frontal cortex of laboratory ro-
dents, which is a model free from polysynaptic and glial inﬂuences
(Popoli et al., 2011). We also asked whether corticosteroids could
modulate the presynaptic CB1R activity in relation to the evoked
release of GABA and glutamate.2. Materials and methods
2.1. Ethics statement and animals
All studies were conducted in accordance with the principles
and procedures outlined as “3Rs” in the guidelines of EU (86/609/
EEC), FELASA, and the National Centre for the 3Rs (the ARRIVE;
Kilkenny et al., 2010), and were approved by the Animal Care
Committee of the Center for Neuroscience and Cell Biology of the
University of Coimbra, Portugal. We also applied the ARRIVE
guideline for the design and execution of in vitro pharmacological
experiments (see below), as well as for data management and
interpretation (McGrath et al., 2010).
In speciﬁc detail, 90 male Wistar rats (180e240 g, 8e10-week
old) were purchased from Charles-River (Barcelona, Spain). Six
CB1 receptor null-mutant (knockout, KO) male mice with a CD-1
background (Ledent et al., 1999) and six of their wild-type litter-
mates (35e45 g, 8e12-week old) were also used in pharmacolog-
ical experiments. Animals were housed with 12 h light on/off cycles
under controlled temperature (23 ± 2 C), and ad libitum access to
food and water. All efforts were made to minimize the number of
animals used and to minimize their stress and discomfort. Animals
used in vitro studies were deeply anesthetized with halothane
before (5%, 1 L/min ﬂow rate) before cervical dislocation.2.2. Subcellular fractionation and Western blotting
After decapitation, rat brains were rapidly collected in ice-cold
Krebs-HEPES assay solution (in mM: NaCl 113, KCl 3, KH2PO4 1.2,
MgSO41.2, CaCl2 2.5, NaHCO3 25, glucose 5.5, HEPES 10), and frontal
cortices were dissected (Paxinos and Watson, 1998). Frontal
cortices were used instead of the much smaller prefrontal cortex to
obtain sufﬁcient amount of protein. To test the presence of GcR in
frontocortical nerve terminals, we prepared a puriﬁed synapto-
some (nerve terminal) fraction from three rats, following Dunkley
et al. (2008). As Fig. 1A and E demonstrate, brain membrane frac-
tions contain high densities of PSD95 - a membrane-bound marker
of post-synapses (Ehlers et al., 1996), whereas this marker is largely
diluted in crude (total) brain homogenate by the copious amounts
of intracellular proteins, and was largely absent in the puriﬁed
synaptosomes. To support the speciﬁcity of the anti-GcR antibody
available to us (Abcam), we tested for GcR translocation from
cytoplasmic to nuclear fractions upon its stimulation with dexa-
methasone (Sarabdjitsingh et al., 2010) (Fig.1AeA1). In brief, frontal
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(450 mm-thick coronal slices). These slices were divided in two
pools per animal, and incubated in 50 mL Krebs-HEPES buffer, and
constantly gassed with 5% CO2, 95% O2 for 1 h at 37 C. Next, one
pool from each animal was treated with dexamethasone (10 mM),
while the other sample was exposed to DMSO (vehicle control,
0.1%) for 30 min under 37 C. After incubation, the slices were
collected, and their cytoplasmic vs. nuclear fractions were sepa-
rated according to Guillemin et al. (2005).
2.3. Quantitative Western blotting with total protein normalization
Protein samples were homogenized by sonication in TNE buffer
(50 mM TriseHCl, 100 mM NaCl, 0.1 mM EDTA, pH 7.4) containing
0.5% Triton X-100 (Sigma), 1% octyl-b-D-glucopyranoside (Calbio-
chem), 5 mM NaF, 100 mM Na3VO4 and a cocktail of protease in-
hibitors (Complete™, Roche). Protein concentrations were
determined by Bradford's colorimetric method (Bradford, 1976).
Aliquots of rat synaptosome and tissue-speciﬁc control lysates
containing: 10 mg protein in 20 mL (for synaptophysin and PSD95
detection) or 20 mg protein in 40 mL (GcR, CB1R) were used. Total
protein labeling was initiated by adding Cy5 dye reagent (GE
Healthcare) that had been pre-diluted (1:10) in ultrapure water.
Samples were mixed and incubated for 30 min at 22e24 C. The
labeling reaction was terminated by adding AmershamWB loading
buffer (GE Healthcare; 20 mL/sample) containing 40 mM dithio-
threitol. Samples were then heated at 95 C for 3 min. Forty mL of
each sample was loaded onto an AmershamWB gel card-14 (13.5%
gel). Electrophoresis (600 V, 45 min) and protein transfer onto
polyvinylidine-diﬂuoride membranes (100 V, 30 min) were at
default settings in an integrated Amersham WB system (GE
Healthcare) for quantitative SDS-PAGE and Western blotting of
proteins with ﬂuorescence detection. Protein samples on mem-
branes were incubated at 4 C overnight with one of the following
primary antibodies: mouse anti-GcR (BuGR2, mouse, monoclonal,
1:500; Abcam), guinea pig anti-CB1R (1:500; kind gift of Dr.
Masahiko Watanabe), mouse b-actin (monoclonal; 1:10,000;
Sigma), rabbit anti-synaptophysin (1:1000; Synaptic Systems) andFig. 1. (A) Immunoblotting of glucocorticoid receptors. Rat cortices were stimulated with d
band at the predicted size of the GcR (96 kDa) was imaged and quantitated. (A1) Quantitativ
immunoreactivity, suggesting that the target band might confer to GcR. (BeE) Qualitative mu
targets detected by Cy3-labeled secondary antibodies. Total protein labeling served as load
aptosome preparation. Both glucocorticoid receptors (B) and CB1 cannabinoid receptors CB1R
adult CB1R knockout (KO) and wild-type mice were used to control the speciﬁcity of the gu
synaptic density protein (PSD95) were immunoblotted to show increased presynaptic abund
as membrane fractions (both from adult mouse cortex) were included. In all cases, three syn
parallel. *P < 0.05 (Student's t-test).rabbit anti-post-synaptic density protein 95 (polyclonal; PSD95;
1:500, Synaptic Systems). To demonstrate the speciﬁcity of the
guinea pig anti-CB1R antibody, we prepared cerebellar homoge-
nates fromwild-type (WT) mice and their CB1R KO littermates. We
found speciﬁc bands at the expectedmolecular weight (~53 kDa) in
the WT mice as well as in the puriﬁed synaptosomes but not in the
CB1R KO mice (Fig. 1C).
Antibody binding was detected by using species-speciﬁc (anti-
rabbit, anti-mouse and anti-guinea pig) carbocyanin (Cy)3-labeled
secondary antibodies (1:1000; GE Healthcare). Membranes were
dried before scanning at 560 nm (Cy3) and 630 nm (Cy5) excitation.
Automated image analysis was performed in the Amersham WB
evaluation software, and optimized by manual editing.
2.4. Tissue processing and histochemistry
Rats were transcardially perfused under deep pentobarbital
anesthesia (50 mg/kg) with a ﬁxative containing 4% para-
formaldehyde (PFA) and 0.1% glutaraldehyde in 0.1 M phosphate-
buffer (PB, pH 7.4), post-ﬁxed in PFA overnight, and subsequently
cryoprotected in 30% sucrose (in PB). Brains were sectioned coro-
nally (50 mm thickness) on a Leica CM1850 cryostat microtome.
Free-ﬂoating sections were rinsed in PB and pre-treated with 0.3%
Triton-X 100 (Sigma, in PB) for 1 h at 22e24 C to enhance the
penetration of antibodies. Non-speciﬁc immunoreactivity was
suppressed by incubating our specimens in a cocktail of 5% normal
donkey serum (Jackson), 1% bovine serum albumin (BSA, Sigma)
and 0.3% Triton X-100 in PB for an additional hour at 22e24 C.
Sections were then exposed to select combinations of primary
antibodies: mouse anti-GcR (BuGR2, 1:500, Abcam) (Sarabdjitsingh
et al., 2010), rabbit anti-VGLUT1 (1:2000; Synaptic Systems)
(Kaneko et al., 2002), rabbit anti-VGAT (1:1,000, Synaptic Systems)
(Martens et al., 2008); goat anti-CB1R (1:1000; Frontier-Science)
(Kawamura et al., 2006) and guinea pig anti-DAGLa (1:500; gift
of Dr. K. Mackie) (Keimpema et al., 2013); diluted in PB (48e72 h at
4 C) to which 0.5% normal donkey serum and 0.3% Triton X-100
had been added. After extensive rinsing in PB, immunoreactivities
were revealed by carbocyanine (Cy) 2, 3 or 5-tagged secondaryexamethasone, which induces the nuclear import of glucocorticoid receptors (GcR). A
e analysis in triplicate experiments shows dexamethasone (10 mM)-induced changes in
ltiplexWestern blotting of total proteins pre-labeled by Cy5 ﬂuorophore and individual
ing control, and was also used to exclude unwanted protein degradation during syn-
s (C) were detected in lysates of rat synaptosome fractions. Cerebellar membranes from
inea pig anti-CB1R antibody (~53 kDa). (D) Synaptophysin (SYN, ~35 kDa) and (E) post-
ance in the puriﬁed synaptosome preparations. For PSD95, total protein lysates, as well
aptosome samples (isolated independently from three rat frontal cortices) were run in
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Lipofuscin autoﬂuorescence was routinely quenched by applying
Sudan Black-B (1%, dissolved in 70% ethanol) (Schnell et al., 1999).
Glass-mounted sections were coverslippedwith Aquamount (Dako,
Glosstrup, Denmark). Images acquired on a 700LSM confocal laser-
scanning microscope (Zeiss). Image surveys were generated using
the tile-scan function with optical zoom ranging from 0.6  to
1.5  at 10  primary magniﬁcation (objective: EC Plan-Neoﬂuar
10  /0.30). Co-localization was deﬁned as immunosignals being
present without physical signal separation in 0.5e0.7-mm optical
slices at 40 (Plan-Neoﬂuar 40  /1.30) or 63  (Plan-Apochromat
63 /1.40) primarymagniﬁcation and at optical zoom ranging from
1e3  . Emission spectra for each dye were limited as follows: Cy2
(505e530 nm), Cy3 (560e610 nm), and Cy5 (650e720 nm). Multi-
panel ﬁgures were assembled in CorelDraw X5 (Corel Corp.).
2.5. CB1R and GcR distribution in the pre- and post-synapse
Preparation of pre- and post-synapse-enriched synaptosomal
fractions from the cerebral cortex of male Wistar rats (n ¼ 3) was
performed as described (Hahn et al., 2009; Phillips et al., 2001). We
used a quantitative proteomic approach to determine CB1R and GcR
levels at subcellular fractions. Brieﬂy, 50 mg proteinwas digested by
trypsin (1:100 w/w%) using a ﬁlter-aided sample preparation pro-
tocol (Manza et al., 2005; Wisniewski et al., 2009). In the three
biological replicates, the pre- and post-synaptic protein fractions
were labeled using TMT 6-plex reagents (channels 126e128 and
129e131, respectively; ThermoFisher Scientiﬁc), according to the
manufacturer's instructions. Then, samples were pooled and frac-
tionated by reversed-phase liquid chromatography (Gilar et al.,
2005). Fractions were analyzed by nanoscale liquid chromatog-
raphy coupled to tandem mass spectrometry (nano-LC-MS/MS;
Bennett et al., 2011). Proteins were identiﬁed bymatching nano-LC-
MS/MS results against a SwissProt database for rat (version
2013.01; 9626 sequences). Relative protein abundance for each
sample was derived from the TMT reporter ion identities.
Data were expressed as means ± S.E.M. of the ratio of pre- and
post-synaptic receptor quantities (i.e. equal amount of receptors at
the two sites corresponds to 1). Student's t-test was used to eval-
uate statistical differences.
2.6. Dual-label [3H]GABA/[14C]glutamate release assay from
cortical nerve terminals and ex vivo brain slices
Experiments were carried out as described (Ferreira et al., 2012;
K€ofalvi et al., 2007), with slight modiﬁcations. Brieﬂy, frontal
cortices were rapidly dissected (as the small size of the prefrontal
cortex did no allow the isolation of sufﬁciently high quantity of
synaptosomes) in 2 mL of ice-cold sucrose solution (0.32 M, con-
taining 5 mM HEPES, pH 7.4). After homogenization with a Teﬂon
homogenizer, and centrifugation at 3000 g for 5 min, the super-
natant was collected and centrifuged at 13,000 g for 10 min to
obtain the P2 synaptosomal fraction.
Synaptosomes - isolated nerve terminals (Whittaker et al.,
1964), represent a preferred tool to study presynaptic processes
free of polysynaptic and glial inﬂuences (Popoli et al., 2011; Raiteri
and Raiteri, 2000). Synaptosomes (in 0.5 mL) were thus simulta-
neously incubated (loaded) with both [3H]GABA (speciﬁc activity,
60 Ci/mmol; ﬁnal concentration, 300 nM) and [14C]glutamate
(200 mCi/mmol; 20 mM) for 10 min, in Krebs-HEPES solution, also
containing aminooxyacetic acid (100 mM), a glutamate decarbox-
ylase and a GABA transaminase inhibitor, to prevent [3H]GABA and
[14C]glutamate metabolism. A 16-microvolume chamber perfusion
setup was ﬁlled with preloaded synaptosomes which were trapped
by layers of Whatman GF/B ﬁlters. Synaptosomes were superfusedcontinuously at a rate of 0.8 mL/min with Krebs-HEPES solution
(37 C) until the end of the experiments. Upon termination of a 10-
min washout and after collecting three 2-min samples as baseline,
neurotransmitter release was stimulated twice (S1, S2) with 10-min
intervals (except where stated otherwise), and with identical
stimuli, ranging from 10 to 75mMKþ or 1 mM 4-aminopyridine (4-
AP). Evoked neurotransmitter release was largely Ca2þ-dependent
and subject to neuromodulation exclusively by presynaptic re-
ceptors (Raiteri and Raiteri, 2000). The intrachamber S2/S1 ratio
served to evaluate the effect of drug treatments. Experiments were
performed in duplicate.
Upon bath application of any substance in the superfusion so-
lution, it remained present until the end of the experiment (that is,
there was no washout study). Corticosteroid agonists, corticoste-
rone (0.1e10 mM) and dexamethasone (0.1e10 mM) and the gluco-
corticoid antagonist, mifepristone, or their vehicle, DMSO were
added 4-min before S2. In a subset of experiments, the interstim-
ulus interval was increased to 20 min, and corticosterone (10 mM)
and dexamethasone (10 mM) or their vehicle, DMSO were present
for 15 min before S2. The CB1R-selective neutral antagonist, O-2050
(1 mM), the CB1R-selective inverse agonist, rimonabant (1 mM) and
the CB2R-selective inverse agonists, AM630 (1 mM) and JTE907were
added 16 min before S1, from the beginning of the preperfusion
period. The mixed CB1R/CB2R agonist WIN55212-2 (1 mM) and the
CB2R-selective agonists, GP1a (100 nM) and JWH133 (0.3 and 3 mM)
or their vehicle, DMSO (0.1%) were added to the superfusion me-
dium 4-min before S2. The concentration of 1 mM for the cannabi-
noid ligands was chosen as the maximal cannabinoid receptor-
selective ligand concentration (see e.g. K€ofalvi et al., 2003, 2007).
The [14C] and [3H] content of each superfusate sample, as well as
the ﬁlters holding the synaptosomes were counted by a dual-label
protocol using a Tricarb b-counter (PerkineElmer). DPM values
were normalized to the ﬁlter content as fractional release (FR%), i.e.
the percent of actual content in the efﬂuent as a function of the total
content.
2.7. Data presentation
All data represent means ± S.E.M. of “n” observations (animals)
in duplicates (release experiments) or triplicates (quantitative
Western blotting). Raw effect data (S2/S1 ratio) on neurotransmitter
release were normalized to the S2/S1 ratio of the DMSO control,
measured from the same animal. Due to the small effect ampli-
tudes, some bar graphs represent data as % change in the S2/S1 ratio
upon treatment as compared to DMSO S2/S1 ratio, which was taken
as 100%. Baseline effect of treatments was compared to the
appropriate control baseline levels in the presence of DMSO vehicle
at a given time point, and expressed as a % change as above. The
principle of effect size calculations was reported earlier by Garç~ao
et al. (2013). Normalized data were tested for normal distribution
by the KolmogoroveSmirnov test. Statistical signiﬁcance was
determined using with Student's paired t-test. One-way ANOVA
followed by Dunett's post-hoc test or by one-sample t-test against
the hypothetical value of 100 (%) for the rest of the data, and
P < 0.05 was accepted for signiﬁcant difference. Tests were per-
formed using the GraphPad Prism 5.0 software package.
2.8. Materials and chemicals
[2,3-3H(N)]GABA and rimonabant: American Radiolabeled
Chemicals, Inc, (Saint Louis, MO, USA); [14C]-U-glutamate: Per-
kineElmer, USA; AM630, WIN55212-2 mesylate and mifepristone:
Abcam Chemicals, Cambridge, UK; corticosterone, HEPES, sucrose,
aminooxyacetic acid, and DMSO: SigmaeAldrich, Sintra, Portugal;
O-2050, dexamethasone, GP1a, JWH133, JTE907: Tocris Bioscience,
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Germany. Non-water soluble substances were diluted in DMSO and
used at a 1:1000 dilution.
3. Results
3.1. Glucocorticoid and CB1 receptors are present in frontocortical
presynapses
First, we asked if GcRs and CB1Rs are present presynaptically,
which would support their ability of direct presynaptic neuro-
modulation. As Fig. 1 illustrates, speciﬁc immunoreactivities for
both GcRs and CB1Rs were present in puriﬁed nerve terminals
(synaptosomes). Puriﬁed synaptosomes were rich in synaptophy-
sin, a presynaptic marker (Rehm et al., 1986) (Fig. 1D), while PSD95,
a major membrane-bound post-synaptic marker (Ehlers et al.,
1996) was relatively modestly detected (Fig. 1E). In the absence of
GcR knock-out mice, we tested the speciﬁcity of the GcR antibody
as follows: dexamethasone treatment is expected to increase the
nuclear transport of the GcR (Sarabdjitsingh et al., 2010), hence we
divided acute frontocortical slices of three rats, and treated them
with either dexamethasone (10 mM) or its vehicle, DMSO, and
subsequently, we isolated cytoplasmic and nuclear proteins for
Western blotting. Thirty min treatment with dexamethasone trig-
gered nuclear import of the GcR, which was represented by a more
than two-fold increase in the ~96 kDa band in the nuclear fraction,
while a decrease in the density of the same band was observed in
the cytoplasmic fraction (Fig. 1A,A').
3.2. GcR localization in relation to CB1R and DAGLa in rat cerebral
cortex
First, we asked whether the subcellular localization of GcRs and
CB1Rs allows for their direct interaction in the cerebral cortex. By
multiple-label histochemistry, GcRs were predominantly localized
to the perikarya of cortical neurons (Fig. 2A). In contrast, CB1Rs
were chieﬂy positioned presynaptically, as suggested by their
overlapping distribution with VGLUT1 (Fig. 2A1,A2). High-
resolution laser-scanning microscopy revealed CB1Rþ/VGATþ ter-
minals apposing GcR-laden neuronal somata and proximal den-
drites in, e.g., the prefrontal cortex (Fig. 2B,B1). We then extended
these observations to the hippocampal formation. We took
advantage of high levels of CB1Rs in glutamatergic terminals in the
inner molecular layer of the dentate gyrus (Monory et al., 2006) to
show dendritic GcR-like labeling in processes receiving dense
CB1Rþ/VGLUT1þ innervation (Fig. 2CeC3). We further extended
these data to CA1 pyramidal neurons (Fig. 2DeD4) by demon-
strating the somatic and dendritic co-existence of GcRs and diac-
ylglycerol lipase a (DAGLa), a post-synaptic enzyme synthesizing 2-
AG (Reisenberg et al., 2012; Yoshida et al., 2006). Next, we sought
independent veriﬁcation of these histochemical ﬁndings by prob-
ing pre- and post-synaptic subcellular fractions for GcR and CB1Rs.
Our analysis conﬁrmed the predominance of CB1Rs in the pre-
synapse. In contrast, GcRs were chieﬂy enriched in the post-
synaptic fraction (Fig. 2E).
3.3. Optimization of the synaptosomal transmitter release assay to
study presynaptic neuromodulation
To achieve optimal signal-to-noise ratio in the receptor-
mediated modulation of evoked transmitter release, one needs to
balance between the stimulus strength and the treatment effect
amplitude (del Carmen Godino et al., 2007). Figs. 3 and 4 depict the
time-course of the release assay for [3H]GABA and [14C]glutamate
when the stimuli (S1 and S2) were by 15 mM Kþ (Figs. 3A, 4A) and30 mM Kþ (Figs. 3B and 4B), or 0.6 mM 4-aminopyridine (4-AP;
Figs. 3C and 4C), in rat. Alternatively, 15 mM Kþ was used in wild-
type (WT) mice (Figs. 3D and 4D). Figs. 3E and 4E summarize the
amplitude of stimulus-evoked transmitter release in the above
stimulation paradigms. Moreover, Figs. 3F and 4F show the inhib-
itory effect of the synthetic cannabinoid agonist, WIN55212-2
(1 mM) being optimal upon depolarization with 15 mM Kþ,
because stronger stimuli substantially reduced the relative
WIN55212-2 (1 mM) effect amplitude - although triggered greater
S1 (and S2) values to work with. In contrast, stimuli weaker than
15 mM Kþ, e.g. with 10 mM Kþ, ampliﬁed the relative effect
amplitude of WIN55212-2 up to ~50% inhibition (data not shown)
in accordance with a previous report (del Carmen Godino et al.,
2007), even though their absolute size was minute. WIN55212-2
triggered even greater relative inhibition of the 4-AP (1 mM)-
evoked release of [14C]glutamate (n ¼ 3, P < 0.05) (Fig. 4F), but
surprisingly, it did not affect the 4-AP-evoked release of [3H]GABA
(n ¼ 3, P > 0.05) (Fig. 3F), thus negating the usefulness of this form
of stimulus for our present aims.
3.4. Corticosteroids do not have robust presynaptic neuromodulator
action in the frontal cortex and the hippocampus
Next, we tested the corticosteroid agonists, dexamethasone and
corticosterone on a high number of animals to allow reliable
detection of presynaptic neuromodulation even in the case of small
effect amplitudes. The release diagrams with dexamethasone
(10 mM) -treatment under different stimulation paradigms in rats
andmice are included in Fig. 3AeD ([3H]GABA) and Fig. 4AeD ([14C]
glutamate), to spare space. Four min preperfusion with dexa-
methasone and corticosterone (0.1e10 mM) did not affect signiﬁ-
cantly the subsequent 15 mM Kþ-evoked release of [3H]GABA and
[14C]glutamate in the rat frontocortical synaptosomes (n ¼ 6e25,
P  0.05 between dexamethasone/corticosterone and DMSO)
(Figs. 5A and 6A). Previously, dexamethasone (10 mM) and corti-
costerone (10 mM) were shown to potentiate the evoked release of
glutamate in hippocampal synaptosomes by ~25% after 10 min
pretreatment (Wang and Wang, 2009). Hence, we increased the
interstimulus interval to 20 min, and added both corticosteroids
15 min before S2. Still, both corticosteroid agonists failed to affect
the evoked release of either transmitter at the concentration of
10 mM (n ¼ 6, P > 0.05; Figs. 5A and 6A). Another difference be-
tween our and the above study was the use of hippocampal syn-
aptosomes and 4-AP stimulation. Hence, we also treated
hippocampal synaptosomes with dexamethasone and applied 4-AP
(0.6 mM) stimulation to evoke the release of [3H]GABA and [14C]
glutamate. Dexamethasone still failed to affect the 4-AP-evoked
release of both transmitters in the hippocampal synaptosomes
(Supplementary Fig. 1A,B). Similarly, dexamethasone (10 mM) did
not affect the release of [3H]GABA (103.6 ± 5.3% of DMSO control,
n ¼ 6, P > 0.05) and [14C]glutamate (99.3 ± 2.2% of DMSO control,
n¼ 5, P > 0.05) evoked by 4-AP (0.6 mM) or by 30 mM Kþ (data not
shown) in frontocortical synaptosomes.
The corticosteroid agonists, either after 4 min or after 15 min,
also did not change the resting outﬂow of the two neurotransmit-
ters, which process is in part Ca2þ-dependent, but mostly Naþ-
dependent and transporter-mediated (Figs. 5B and 6B). The only
exception was that after 4 min of perfusion, 1 mM dexamethasone
produced a small (5.5%) but signiﬁcant increase in the resting
glutamate outﬂow (n ¼ 10, P < 0.05) (Fig. 6B).
Next, we asked if by any chance the presynaptic GcRs were
under constitutive activity which could mask any effect for dexa-
methasone. We thus tested mifepristone on the S2/S1 ratio of both
transmitters. Mifepristone is a potent GcR antagonist with
Kd < 1 nM (Baulieu, 1989). Mifepristone, at the concentration of
Fig. 2. Correlated localization of glucocorticoid and cannabinoid (type 1) receptors in rat forebrain. (A-A2) Overview of GcR, VGLUT1 and CB1R immunoreactivities in the rat
infragranular neocortex (layers 5 and 6). GcRþ somata were typically identiﬁed in deep neocortical layers (A). In turn, VGLUT1 and CB1R were localized to an axonal meshwork
leaving somatodendritic positions unlabeled (A1,A2). In the prefrontal cortex, VGATþ/CB1Rþ dual-labeled nerve terminals (open arrowheads) were visualized around the peri-
somatic segment of cortical neurons containing GcRs post-synaptically (B1,B2). We then extended these ﬁndings to the hippocampus where dentate granule cells (gc, arrowhead)
and hilar neurons (open arrowhead) qualitatively contained moderate and high GcR levels, respectively (C). Inset shows a GcRþ process with apposing VGLUT1þ/CB1Rþ nerve
endings (open arrowheads; C1eC3). Next, we tested whether the subcellular positioning of DAGLa, an endocannabinoid synthesis enzyme expressed post-synaptically (Yoshida
et al., 2006), overlaps with that of GcRs. We found DAGLaþ proﬁles proximal to GcR-labeled post-synaptic structures (D). Closely associated GcR/DAGLa puncta apposed CB1Rþ
afferents, supporting post-synaptic GcR localization (D1-D4). (E) Next, we used quantitative proteomics upon TMT-labeling of pre- and post-synaptic fractions to quantitatively
conﬁrm subcellular CB1R and GcR load. CB1Rs were predominantly presynaptic (pre/post ratio >1). In contrast, GcRs were primarily enriched in the post-synapse (pre/post ratio <1).
Data are from n ¼ 3 preparations; **P < 0.05. Abbreviations: cc, corpus callosum; gc, granule cell; L, layer of neocortex. Scale bars ¼ 200 mm (A-A2), 20 mm (B1,C), 7 mm (C3,D), 2 mm
(D4).
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either the resting or the evoked release of both transmitters
(Supplementary Figs. 2,3), suggesting the lack of endogenous GcR
activity in our system, which is indeed what one expects in
superfused synaptosomes. In the low micromolar range however,
mifepristone strongly depressed both the resting and the
15 mM Kþ-evoked release of both transmitters, which was not
prevented by the co-administration of dexamethasone at high
concentrations (10 and 30 mM) (Supplementary Figs. 2,3). This
serves as an additional proof of that mifepristone's action is unre-
lated to an antagonism at putative constitutively active GcRs. To
further investigate the underlying mechanisms of mifepristone's
action is beyond the scope of this study, but additional discussion
can be found in the Supplementary Material.3.5. Pharmacological characterization of presynaptic cannabinoid
action
WIN55212-2 is a potent, non-selective agonist of both the CB1R
and the CB2R (Pertwee et al., 2010). The CB1R-selective neutral
antagonist, O-2050 (1 mM) (Pertwee et al., 2010) fully abolished the
inhibitory action of WIN55212-2 on the 15 mM Kþ-evoked release
of both [3H]GABA (n ¼ 10) (Fig. 7A) and [14C]glutamate (n ¼ 9)
(Fig. 7B). Recently, CB2Rs have been reported to heterodimerize
with CB1Rs in forebrain GABA-ergic interneurons (Callen et al.,
2012), and these heterodimers might mediate the cannabinoid in-
hibition on the Kþ-evoked release of [3H]GABA in hippocampal
synaptosomes (Ando et al., 2012). Therefore, we retested
WIN55212-2 in the presence of the CB2R-selective inverse agonist,
JTE907 (1 mM). CB2R blockade did not signiﬁcantly affect theinhibitory action of WIN55212-2 on the evoked release of either
neurotransmitter (n ¼ 4, P > 0.05 between WIN55212-2 vs.
WIN55212-2 þ JTE907 combined) (Fig. 7A,B). For curiosity, we also
tested the CB2R-selective agonists, GP1a (100 nM) (Murineddu
et al., 2006) and JWH133 (0.3 and 3 mM) (Huffman et al., 1999)
and both of them were devoid of effect on either the resting or the
evoked transmitter releases (n ¼ 4e6; P > 0.05 vs. DMSO control)
(Fig. 7A,B). Additional pharmacological characterizations of the
sensitivity of the effect of WIN55212-2 to the CB1R inverse agonist,
rimonabant and the CB2R inverse agonist, AM630 have been carried
out as illustrated by Supplementary Fig. 4. However these data
suggest maintaining a cautious approach on relying on rimonabant
and AM630 in similar assays.
Finally, to conﬁrm the role of the CB1R, we assayed WIN55212-2
in frontocortical synaptosomes isolated from both the CB1R KO
mice and their WT littermate mice. WIN55212-2 inhibited the
evoked release of [3H]GABA and of [14C]glutamate in WT mice
(n¼ 6, P< 0.05 betweenWIN55212-2 and DMSO; Fig. 7A,B), but not
in the CB1R KO littermates (n ¼ 6, P > 0.05 between WIN55212-2
and DMSO; Fig. 7A,B). The tendency of WIN55212-2 to decrease
the evoked release of [14C]glutamate in the CB1R KO mice has been
previously observed and is probably related to either a direct Ca2þ
channel antagonism (which was still not signiﬁcant at 1 mM of this
cannabinoid (K€ofalvi et al., 2007)) or a putative developmental
compensation by CB2Rs in glutamatergic terminals.3.6. Corticosteroids do not affect presynaptically the
neuromodulator action of the CB1R in the frontal cortex
Next we asked if glucocorticoids could interfere with the
Fig. 3. Release diagrams and relative values of the release of [3H]GABA, evoked with various stimulation paradigms in rat and mouse frontocortical synaptosomes and of the
inhibitory action of the CB1R agonist WIN55212-2 (1 mM) under selected stimulation paradigms. (AeD) Release diagram for the release of [3H]GABA under the following conditions:
two identical stimuli (S1 and S2) with (A) 15 mM Kþ, (B) 30 mM Kþ, (C) 4-aminopyridine (4-AP; 0.6 mM) - all in rats, and (D) 15 mM Kþ in the CD-1 wild-type mice. N  6, *P < 0.05.
Note that all four panels display the mean ± S.E.M. of experiments with the synthetic cannabinoid, WIN55212-2 (1 mM; blue triangles), and the glucocorticoid, dexamethasone
(10 mM; orange downward triangles) as well as their vehicle control, DMSO (0.1% control; red circles). All substances were administered in the superfusion medium according to the
horizontal bar. FR%, fractional release %, i.e. the release value relative to the total synaptosomal content at any given time-point. (E) The comparison of the amplitudes of the [3H]
GABA release, evoked by different stimuli in the rats and the mice. N  6. (F) The amplitude of the effect of the synthetic cannabinoid agonist, WIN55212-2 (1 mM) on the release of
[3H]GABA release, evoked by different stimuli in the rats and the mice. WT: wild type. The red dashed line represents the vehicle DMSO control. All data are mean ± S.E.M. of N  6
obsevations, *P < 0.05, ***P < 0.001. Dexamethasone effects are quantiﬁed in Fig. 5. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the
web version of this article.)
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administered WIN55212-2 (1 mM) with corticosteroid agonists.
The amplitude of inhibition by WIN55212-2 was not signiﬁcantly
altered either by corticosterone (10 mM; n ¼ 7, P > 0.05 for both
neurotransmitters) or by dexamethasone (10 mM; n ¼ 11, P > 0.05
for both neurotransmitters) (Fig. 8A,B). Finally, dexamethasone did
not affect the 15 mM Kþ-evoked release of [3H]GABA and [14C]
glutamate in either WT or CB1R KO mice (Fig. 8A,B).
4. Discussion
While acute stress increases ﬁtness and therefore is benign,
chronic elevation of plasma corticosteroid levels can trigger
neurological and psychiatric illnesses, including memory loss,
hypoplasticity, depression, post-traumatic stress disorder and
neurodegeneration (Bitencourt et al., 2013; Detka et al., 2013; Jo€els
et al., 2012; Mora et al., 2012). As our knowledge on subacute
(genomic) and/or post-synaptic modulation of synaptic plasticity
by corticosteroids is greatly expanding (Jo€els et al., 2012; Maggio
and Segal, 2012; Sebastian et al., 2013), we asked now ifcorticosteroids can also serve as fast direct presynaptic neuro-
modulators, either on their own or involving the CB1 cannabinoid
receptor (CB1R).
An important conclusion of this study is that glucocorticoid
receptors (GcRs) are present at the frontocortical presynapse at low
density. Moreover, the subsynaptic mapping of the two receptors
revealed post-synaptic preference for GcRs and predominantly
presynaptic location for CB1Rs in the cerebral cortex. Also, VGATþ
nerve endings in the prefrontal cortex and VGLUT1þ terminals in
the hippocampus were found to face apposing post-synaptic
compartments rich in GcRs. An additional staining revealed that
immunoreactivity for DAGLa, a major enzyme that produce the
endocannabinoid, 2-arachydonoylglycerol brain (Reisenberg et al.,
2012; Yoshida et al., 2006), is adjacent to GcR immunoreactivity.
These all suggest a complex trans-synaptic interaction between
corticosteroids and the endocannabinoid system.
But according to the preferentially post-synaptic distribution of
GcRs, we did not ﬁnd corticosteroids to exert robust rapid pre-
synaptic modulation of either the resting or the depolarization-
evoked release of GABA and glutamate in isolated presynapses. To
Fig. 4. Release diagrams and relative values of the release of [14C]glutamate, evoked with various stimulation paradigms in rat and mouse frontocortical synaptosomes and of the
inhibitory action of the CB1 receptor agonist WIN55212-2 (1 mM) under selected stimulation paradigms. (AeD) Release diagram for the release of [14C]glutamate under the following
conditions: two identical stimuli (S1 and S2) with (A) 15 mM Kþ, (B) 30 mM Kþ, (C) 4-aminopyridine (4-AP; 1 mM) - all in rats, and (D) 15 mM Kþ in the CD-1 wild-type mice. N  6,
*P < 0.05. Note that all four panels display the mean ± S.E.M. of experiments with the synthetic cannabinoid, WIN55212-2 (1 mM; blue triangles), and the glucocorticoid, dexa-
methasone (10 mM; orange downward triangles) as well as their vehicle control, DMSO (0.1% control; red circles). All substances were administered in the superfusion medium
according to the horizontal bar. FR%, fractional release %, i.e. the release value relative to the total synaptosomal content at any given time-point. (E) The comparison of the
amplitudes of the [14C]glutamate release, evoked by different stimuli in the rats and the mice. N  6, *P < 0.05. (F) The amplitude of the effect of the synthetic cannabinoid agonist,
WIN55212-2 (1 mM) on the release of [14C]glutamate release, evoked by different stimuli in the rats and the mice. WT: wild type. The red dashed line represents the vehicle DMSO
control. All data are mean ± S.E.M. of N  6 obsevations, *P < 0.05, ***P < 0.001. Dexamethasone effects are quantiﬁed in Fig. 6. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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scale, presynaptic receptors should be linked with voltage-gated
Ca2þ channels (VGCCs) and/or Kþ channels (Jong and Fioravante,
2014; Kim and Hoffman, 2008). The CB1R has been shown to
operate via both the inactivation of VGCCs and the activation of
outward Kþ currents (Howlett et al., 2010). In contrast, corticoste-
roid receptors are known as indirect modulators of VGCCs via
genomic mechanisms in the limbic system, rather than fast regu-
lators of Ca2þ signaling (Jo€els and Karst, 2012). This would likely
preclude the modulation of Ca2þ-dependent evoked release by
both GcRs and mineralocorticoid receptors (McRs) in the synap-
tosomes, which explains in our study the lack of robust cortico-
steroid action on the evoked release of GABA and glutamate either
in the frontal cortex or the hippocampus. This somewhat contra-
dicts the strong facilitation seen byWang andWang (2009). In that
study, the authors used ﬂuorimetric detection of endogenously
released glutamate with single 4-AP stimulation. Based on the ionic
composition of their assay medium, we speculate that their gluta-
mate release was more Naþ- and less Ca2þ-dependent than ours,
and that type of release can be better facilitated through theinhibition of hyperpolarizing Kþ channels. Indeed, McRs are
reportedly negatively associated with some forms of Kþ channels in
the hippocampus, increasing the likeliness of depolarization when
a subtreshold stimulus reaches the glutamatergic terminal (Karst
et al., 2005; Olijslagers et al., 2008). A blockade of Kþ channels
also can explain how dexamethasone (1 mM) increased by ~5% the
resting release of glutamate in our assay.
Another form of presynaptic priming is likely associated with
the modulation of vesicular release: recent studies reported that
stress and (pre)frontocortical GcR activation increase the readily
releasable pool of glutamate (Popoli et al., 2011; Treccani et al.,
2014). Notably, this form of plasticity requires additional signals
coincident with glucocorticoids in the living animal, because in the
above study, acute stress ex vivo could increase the depolarization-
induced release of glutamate in the rat (pre)frontal cortex, but the
in vitro application of the stress hormone corticosterone was not
sufﬁcient alone to achieve the same result (Treccani et al., 2014).
In the present study we also asked if the activation of CB1Rs was
that additional signal: although glucocorticoids directly did not
modulate the release, a putative crosstalk between the
Fig. 5. Dexamethasone and corticosterone do not affect either (A) the evoked or (B) the resting release of [3H]GABA in frontocortical synaptosomes. The corticosteroid agonists were
added 4 or 15 min before S2 at the concentrations of 0.1, 1 and 10 mM (as indicated right below the bars). Due to small effect amplitudes, bars correspond to the % changes in the S2/S1
ratio, as compared to DMSO control taken as 100%, here represented with the 0% line. The discrepancy in the sample numbers for the dexamethasone (10 mM, 4 min) and
corticosterone (10 mM, 4 min) data between panels (A) and (B) arises from that the effect of the two drugs on the resting release was also determined after 4 min perfusion in the 15-
min-perfusion experiments, and this accounts for additional 6 data points. All data are mean ± S.E.M. of N  6 obsevations, as indicated under the bars; n.s., not signiﬁcant. Consult
also with Supplementary Fig. 1A.
Fig. 6. Dexamethasone and corticosterone do not affect either (A) the evoked or (B) the resting release of [14C]glutamate in frontocortical synaptosomes. The corticosteroid agonists
were added 4 or 15 min before S2 at the concentrations of 0.1, 1 and 10 mM (as indicated right below the bars). In panel (A), a small but signiﬁcant increase in the resting [14C]
glutamate outﬂow is displayed upon 1 mM dexamethasone. Due to small effect amplitudes, bars correspond to the % changes in the S2/S1 ratio, as compared to DMSO control taken
as 100%, here represented with the 0% line. All data are mean ± S.E.M. of N  6 obsevations, as indicated under the bars; n.s., not signiﬁcant, *P < 0.05. The discrepancy in the sample
numbers for the dexamethasone (10 mM, 4 min) and corticosterone (10 mM, 4 min) data between panels (A) and (B) arises from that the effect of the two drugs on the resting release
was also determined after 4 min perfusion in the 15-min-perfusion experiments, and this accounts for additional 6 data points. Consult also with Supplementary Fig. 1B.
Fig. 7. Pharmacology of presynaptic CB1Rs in (A) GABA-ergic and (B) glutamatergic nerve terminals of the frontal cortex. Due to small effect amplitudes, bars correspond to the %
changes in the S2/S1 ratio, as compared to DMSO control taken as 100%, here represented with the 0% line. For further details, see Materials and Methods as well as legends to Figs. 3
and 4. All data are mean ± S.E.M. of the indicated sample numbers after the bars (i.e. animal in duplicate). WT, wild-type mice; KO, CB1R KO mice. *P < 0.05, **P < 0.01, ***P < 0.001;
n.s., not signiﬁcant.
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Fig. 8. Dexamethasone (10 mM) and corticosterone (10 mM) do not signiﬁcantly affect the inhibitory action of the CB1R on the 15 mM Kþ-evoked release of either (A) [3H]GABA and
(B) [14C]glutamate, and the lack of dexamethasone effect is unchanged in the CB1R KO mice as compared to the WT littermates. Due to small effect amplitudes, bars correspond to
the % changes in the S2/S1 ratio, as compared to DMSO control taken as 100%, here represented with the 0% line. All data are mean ± S.E.M. of the indicated sample numbers after the
bars (i.e. animal in duplicate). WT, wild-type mice; KO, CB1R KO mice. *P < 0.05, **P < 0.01, ***P < 0.001; n.s., not signiﬁcant.
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considered in two forms: either corticosteroids could prevent the
CB1R from inhibiting the release of a neurotransmitter, or they
could trigger an alternative second messenger system that facili-
tates transmitter release. Certainly, these assumptions are
compelling because the endocannabinoid system has been
reportedly recruited upon cerebral GcR receptor activation: a) the
systemic injection of corticosterone rapidly increases endocanna-
binoid levels in limbic areas (Atsak et al., 2012; Hill et al., 2010); b)
restraint stress causes a parallel increase of corticosterone levels in
the plasma and endocannabinoid levels in the medial prefrontal
cortex (Hill et al., 2011); c) application of corticosterone to pre-
frontocortical slices triggers endocannabinoid release to activate
CB1Rs in GABA-ergic terminals contacting pyramidal cells (Hill
et al., 2011); and d) dexamethasone and corticosterone rapidly
suppress glutamatergic transmission via endocannabinoid release
and retrograde signaling in the hypothalamic paraventricular nu-
cleus (Di et al., 2003). Our immunohistochemical data and the
analysis of the subsynaptic localization of the receptors, together
with the above references (a-d) support a testable arrangement in
which the interaction between the two signaling systems is prin-
cipally indirect, i.e. that glucocorticoids trigger endocannabinoid
release in the post-synaptic compartment, which then activate
juxtapositioned presynaptic CB1 receptors via trans-synaptic
retrograde endocannabinoid signaling, as postulated before (Hill
and McEwen, 2009).
Additionally, the CB1R is prone to interact with various receptors
(Dalton and Howlett, 2012; Ferreira et al., 2015), and frequently, the
partner receptor either silences the CB1R-mediated inhibition of
e.g. evoked glutamate release (Ferreira et al., 2015), or the two
interacting receptors may change their coupling to Gs to facilitate
cAMP accumulation and transmitter release (Glass and Felder,
1997). As a result, a putative presynaptic CB1R-GcR heterodimer
can have important consequences on the (patho)physiology of the
prefrontal cortex.
Despite these cross-correlative data and the fact that both
corticosteroid receptors and CB1Rs can modulate Kþ channels, our
pharmacological interrogation does not reveal a robust direct
presynaptic interaction between these signaling systems. Besides
the low presynaptic GcR density, this can be once again a question
of sensitivity: the rapid inhibitory responses that the CB1R can
trigger via either the closure of VGCCs or the opening of Kþ chan-
nels apparently occur in separated pools of cortical nerve terminals,
as revealed by a previous study (del Carmen Godino et al., 2007). In
that study, WIN55212-2 was much more effective in relative terms
(up to 80%) to inhibit the low (5 mM Kþ) stimulus strength-evoked
release via Kþ channel opening. But by increasing the stimulusstrength, VGCCs also get gradually recruited and become respon-
sible for the majority of the net glutamate efﬂux (del Carmen
Godino et al., 2007). This prompts the hypothesis that under
certain circumstances, McRs/GcRs and CB1Rs may be able to
compete for the modulation of Kþ channels in a subset of nerve
terminals, but the overall outcome would be small. Altogether, we
believe now that any direct rapid presynaptic neuromodulator ac-
tion of corticosteroids could be better monitored in either patch
clamp electrophysiology or in synaptosomal release experiments
with greater sensitivity - e.g. via ﬂuorimetric batch enzyme assay.
As a drawback, the latter technique may narrow down the use of
the assay for limited types of neurotransmitters such as glutamate.
Furthermore, as this type of modulation requires minimal depo-
larization, we expect no robust rapid presynaptic response to
corticosteroid treatment.
The low presynaptic GcR density can indeed mask effect am-
plitudes in a batch assay via the dilution of the response by those
nerve terminals that do not bear the receptor. For instance, in slice
patch-clamp experiments, which allows observing unitary con-
nections established by CB1R-bearing nerve terminals and hence no
dilution of effect takes place, WIN55212-2 (2 mM) inhibits GABA-
ergic synaptic transmission in the rat PFC by ~35% (Hill et al.,
2010). Similarly, as shown by Lafourcade and colleagues (2007),
the highest CB1R-mediated inhibition of glutamatergic trans-
mission is ~40% in the mouse PFC. These effect amplitudes can be
greatly diluted in a pool of synaptosomes by those terminals which
do not bear CB1R. The frontal cortex shows layer cake-type CB1R
staining: Layers IIeIII, Va and VI express high density of the CB1R
while layers I, IV and Vb express little (Bodor et al., 2005; Ferreira
et al., 2012; Marsicano and Lutz, 1999). Nerve terminals from the
CB1R-poor regions also contribute to [3H]GABA and [14C]glutamate
release but will not respond to CB1R activation. The samemay occur
with the GcR and the McR. Hence, the best method to map how
corticosteroids affect synaptic plasticity is still the use of electro-
physiology in slices, but the drawback of that technique is that the
measured response is frequently the resultant of changes in the
tripartite synapse, protein synthesis, receptor trafﬁcking and
polysynaptic inputs (Maggio and Segal, 2012).
Other models in which key ﬁndings on synaptic effects have
been gathered are cell cultures. Studies on neural cell lines and
primary cell cultures revealed the complex nature by which McRs
and GcRs can trigger spatiotemporally distinct genomic and non-
genomic responses, which can lead to changes in the expression
and the clustering of pre- and post-synaptic proteins as well as to
alterations in dendritic spine morphology (Chatterjee and Sikdar,
2014; Morsink et al., 2006; Sebastian et al., 2013). Of note, den-
dritic degeneration also occurs in vivo, as documented in the layers
R.M. Bitencourt et al. / Neurochemistry International 90 (2015) 72e8482II/III of the medial PFC of rats after chronic (4-week) treatment with
either dexamethasone or corticosterone (Cerqueira et al., 2007).
In conclusion, despite that a part of our data is negative, our
thorough analysis of the presynaptic action of corticosteroids
contributes to the better understanding of the rapid mechanisms




List of author contribution
Study design: RMB, RNT, TH and AK. Release experiments: RMB,
BSP, CLemos, SGF, and AK. Knockout and wild-type mice (geno-
typing, transport): CLedent. Subcellular fractionation and Western
blotting, confocal microscopy: VC, AA, SGF, and TH. Subsynaptic
analysis: FJS, GL, TH. Financial support of the study: AK, RNT, TH and
RAC. First draft: AK. Final form of the manuscript: all authors.
Acknowledgments
This work was supported by Vetenskapsrådet (T.H.), European
Comission “PAINCAGE” grant (T.H.), Novo Nordisk Foundation
(T.H.), the Petrus & Augusta Hedlunds' Foundation (T.H.), Coor-
denaç~ao de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
(R.M.B.), Conselho Nacional de Desenvolvimento Cientíﬁco e Tec-
nologico (CNPq) (R.M.B.), FEDER, COMPETE, PEst-C/SAU/LA0001/
2013e2014, and the strategic project UID/NEU/04539/2013 (S G F.,
B.S.P., C.L., R.A.C. and A.K.), PTDC/SAU-NEU/100729/2008 (from the
Portuguese Government, A.K.), SFRH/BPD/85738/2012 (from the
Portuguese Government, S.G.F.) and PTDC/SAU-NSC/122254/2010
(from the Portuguese Government, R.A.C.) and W911NF-10-1-
0059 (from DARPA, R.A.C.). The authors thank Dr. K. Mackie (Indi-
ana University) for his generous gift of an anti-DAGLa antibody.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.neuint.2015.07.014.
References
Ando, R.D., Bíro, J., Cs€olle, C., Ledent, C., Sperlagh, B., 2012. The inhibitory action of
exo- and endocannabinoids on [3H]GABA release are mediated by both CB1 and
CB2 receptors in the mouse hippocampus. Neurochem. Int. 60, 145e152. http://
dx.doi.org/10.1016/j.neuint.2011.11.012.
Atsak, P., Hauer, D., Campolongo, P., Schelling, G., McGaugh, J.L., Roozendaal, B.,
2012. Glucocorticoids interact with the hippocampal endocannabinoid system
in impairing retrieval of contextual fear memory. Proc. Natl. Acad. Sci. U. S. A.
109, 3504e3509. http://dx.doi.org/10.1073/pnas.1200742109.
Baulieu, E.E., 1989. Contragestion and other clinical applications of RU 486, an
antiprogesterone at the receptor. Science 245, 1351e1357.
Bennett, K.L., Funk, M., Tschernutter, M., Breitwieser, F.P., Planyavsky, M., Ubaida
Mohien, C., Muller, A., Trajanoski, Z., Colinge, J., Superti-Furga, G., Schmidt-
Erfurth, U., 2011. Proteomic analysis of human cataract aqueous humour:
comparison of one-dimensional gel LCMS with two-dimensional LCMS of
unlabelled and iTRAQ(R)-labelled specimens. J. Proteomics 74, 151e166.
Bitencourt, R.M., Pamplona, F.A., Takahashi, R.N., 2013. A current overview of can-
nabinoids and glucocorticoids in facilitating extinction of aversive memories:
potential extinction enhancers. Neuropharmacology 64, 389e395. http://
dx.doi.org/10.1016/j.neuropharm.2012.05.03.
Bitencourt, R.M., Pamplona, F.A., Takahashi, R.N., 2014. Corticosteroid-endocanna-
binoid loop supports decrease of fear-conditioned response in rats. Eur. Neu-
ropsychopharmacol. 24, 1091e1102. http://dx.doi.org/10.1016/
j.euroneuro.2014.01.010.
Bodor, A.L., Katona, I., Nyíri, G., Mackie, K., Ledent, C., Hajos, N., Freund, T.F., 2005.
Endocannabinoid signaling in rat somatosensory cortex: laminar differences
and involvement of speciﬁc interneuron types. J. Neurosci. 25, 6845e6856.
http://dx.doi.org/10.1523/JNEUROSCI.3060-09.2009.Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of micro-
gram quantities of protein utilizing the principle of protein-dye binding. Anal.
Biochem. 72, 248e254.
Callen, L., Moreno, E., Barroso-Chinea, P., Moreno-Delgado, D., Cortes, A., Mallol, J.,
Casado, V., Lanciego, J.L., Franco, R., Lluis, C., Canela, E.I., McCormick, P.J., 2012.
Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J. Biol.
Chem. 287, 20851e20865. http://dx.doi.org/10.1074/jbc.M111.335273.
Cerqueira, J.J., Taipa, R., Uylings, H.B., Almeida, O.F., Sousa, N., 2007. Speciﬁc
conﬁguration of dendritic degeneration in pyramidal neurons of the medial
prefrontal cortex induced by differing corticosteroid regimens. Cereb. Cortex 17,
1998e2006.
Chaouloff, F., Groc, L., 2011. Temporal modulation of hippocampal excitatory
transmission by corticosteroids and stress. Front. Neuroendocrinol. 32, 25e42.
http://dx.doi.org/10.1016/j.yfrne.2010.07.004.
Chatterjee, S., Sikdar, S.K., 2014. Corticosterone targets distinct steps of synaptic
transmission via concentration speciﬁc activation of mineralocorticoid and
glucocorticoid receptors. J. Neurochem. 128, 476e490. http://dx.doi.org/10.1111/
jnc.12478.
Chen, Y., Andres, A.L., Frotscher, M., Baram, T.Z., 2012. Tuning synaptic transmission
in the hippocampus by stress: the CRH system. Front. Cell. Neurosci. 6, 13.
http://dx.doi.org/10.3389/fncel.2012.00013.
Dalton, G.D., Howlett, A.C., 2012. Cannabinoid CB1 receptors transactivate multiple
receptor tyrosine kinases and regulate serine/threonine kinases to activate ERK
in neuronal cells. Br. J. Pharmacol. 165, 2497e2511. http://dx.doi.org/10.1111/
j.1476-5381.2011.01455.x.
de Jong, A.P., Fioravante, D., 2014. Translating neuronal activity at the synapse:
presynaptic calcium sensors in short-term plasticity. Front. Cell. Neurosci. 8,
356. http://dx.doi.org/10.3389/fncel.2014.00356.
del Carmen Godino, M., Torres, M., Sanchez-Prieto, J., 2007. CB1 receptors diminish
both Ca2þ inﬂux and glutamate release through two different mechanisms
active in distinct populations of cerebrocortical nerve terminals. J. Neurochem.
101, 1471e1482. http://dx.doi.org/10.1111/j.1471-4159.2006.04422.x.
Detka, J., Kurek, A., Basta-Kaim, A., Kubera, M., Lason, W., Budziszewska, B., 2013.
Neuroendocrine link between stress, depression and diabetes. Pharmacol. Rep.
P. R. 65, 1591e1600 (doi).
Di, S., Malcher-Lopes, R., Halmos, K.C., Tasker, J.G., 2003. Nongenomic glucocorticoid
inhibition via endocannabinoid release in the hypothalamus: a fast feedback
mechanism. J. Neurosci. Off. J. Soc. Neurosci. 23, 4850e4857 doiPubmed.
Dunkley, P.R., Jarvie, P.E., Robinson, P.J., 2008. A rapid percoll gradient procedure for
preparation of synaptosomes. Nat. Protoc. 3, 1718e1728. http://dx.doi.org/
10.1038/nprot.2008.171.
Egertova, M., Elphick, M.R., 2000. Localisation of cannabinoid receptors in the rat
brain using antibodies to the intracellular C-terminal tail of CB. J. Comp. Neurol.
422, 159e171 doi.
Ehlers, M.D., Mammen, A.L., Lau, L.F., Huganir, R.L., 1996. Synaptic targeting of
glutamate receptors. Curr. Opin. Cell Biol. 8, 484e489 doi.
Ferreira, S.G., Gonçalves, F.Q., Marques, J.M., Tome, A^.R., Rodrigues, R.J., Nunes-
Correia, I., Ledent, C., Harkany, T., Venance, L., Cunha, R.A., K€ofalvi, A., 2015.
Presynaptic adenosine A2A receptors dampen cannabinoid CB1 receptor-
mediated inhibition of corticostriatal glutamatergic transmission. Br. J. Phar-
macol. 172, 1074e1086. http://dx.doi.org/10.1111/bph.12970.
Ferreira, S.G., Teixeira, F.M., Garç~ao, P., Agostinho, P., Ledent, C., Cortes, L., Mackie, K.,
K€ofalvi, A., 2012. Presynaptic CB1 cannabinoid receptors control frontocortical
serotonin and glutamate releaseespecies differences. Neurochem. Int. 61,
219e226. http://dx.doi.org/10.1016/j.neuint.2012.05.009.
Garç~ao, P., Szabo, E.C., Wopereis, S., Castro, A.A., Tome, A^.R., Prediger, R.D.,
Cunha, R.A., Agostinho, P., K€ofalvi, A., 2013. Functional interaction between pre-
synaptic a6b2-containing nicotinic and adenosine A2A receptors in the control
of dopamine release in the rat striatum. Br. J. Pharmacol. 169, 1600e1611. http://
dx.doi.org/10.1111/bph.12234.
Gilar, M., Olivova, P., Daly, A.E., Gebler, J.C., 2005. Two-dimensional separation of
peptides using RP-RP-HPLC system with different pH in ﬁrst and second sep-
aration dimensions. J. Sep. Sci. 28, 1694e1703.
Glass, M., Felder, C.C., 1997. Concurrent stimulation of cannabinoid CB1 and dopa-
mine D2 receptors augments cAMP accumulation in striatal neurons: evidence
for a Gs linkage to the CB1 receptor. J. Neurosci. Off. J. Soc. Neurosci. 17,
5327e5333.
Guillemin, I., Becker, M., Ociepka, K., Friauf, E., Nothwang, H.G., 2005. A subcellular
prefractionation protocol for minute amounts of mammalian cell cultures and
tissue. Proteomics 5, 35e45. http://dx.doi.org/10.1002/pmic.200400892.
Hahn, C.G., Banerjee, A., Macdonald, M.L., Cho, D.S., Kamins, J., Nie, Z., Borgmann-
Winter, K.E., Grosser, T., Pizarro, A., Ciccimaro, E., Arnold, S.E., Wang, H.Y.,
Blair, I.A., 2009. The post-synaptic density of human postmortem brain tissues:
an experimental study paradigm for neuropsychiatric illnesses. PLoS One 4,
e5251.
Herman, J.P., Prewitt, C.M., Cullinan, W.E., 1996. Neuronal circuit regulation of the
hypothalamo-pituitary-adrenocortical stress axis. Crit. Rev. Neurobiol. 10,
371e394.
Hill, E.L., Gallopin, T., Ferezou, I., Cauli, B., Rossier, J., Schweitzer, P., Lambolez, B.,
2007. Functional CB1 receptors are broadly expressed in neocortical GABAergic
and glutamatergic neurons. J. Neurophysiol. 97, 2580e2589. http://dx.doi.org/
10.1152/jn.00603.2006.
Hill, M.N., McEwen, B.S., 2009. Endocannabinoids: the silent partner of glucocor-
ticoids in the synapse. Proc. Natl. Acad. Sci. U. S. A. 106, 4579e4580. http://
dx.doi.org/10.1073/pnas.0901519106.
R.M. Bitencourt et al. / Neurochemistry International 90 (2015) 72e84 83Hill, M.N., McLaughlin, R.J., Bingham, B., Shrestha, L., Lee, T.T.Y., Gray, J.M.,
Hillard, C.J., Gorzalka, B.B., Viau, V., 2010. Endogenous cannabinoid signaling is
essential for stress adaptation. Proc. Natl. Acad. Sci. U. S. A. 107, 9406e9411.
http://dx.doi.org/10.1073/pnas.0914661107.
Hill, M.N., McLaughlin, R.J., Pan, B., Fitzgerald, M.L., Roberts, C.J., Lee, T.T.-Y.,
Karatsoreos, I.N., Mackie, K., Viau, V., Pickel, V.M., McEwen, B.S., Liu, Q.,
Gorzalka, B.B., Hillard, C.J., 2011. Recruitment of prefrontal cortical endo-
cannabinoid signaling by glucocorticoids contributes to termination of the
stress response. J. Neurosci. Off. J. Soc. Neurosci. 31, 10506e10515. http://
dx.doi.org/10.1523/JNEUROSCI.0496-11.2011.
Hill, M.N., Tasker, J.G., 2012. Endocannabinoid signaling, glucocorticoid-mediated
negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis.
Neuroscience 204, 5e16. http://dx.doi.org/10.1016/j.neuroscience.2011.12.030.
Howlett, A.C., Blume, L.C., Dalton, G.D., 2010. CB1 cannabinoid receptors and their
associated proteins. Curr. Med. Chem. 17, 1382e1393.
Huffman, J.W., Liddle, J., Yu, S., Aung, M.M., Abood, M.E., Wiley, J.L., Martin, B.R.,
1999. 3-(1’,1’-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds:
synthesis of selective ligands for the CB2 receptor. Bioorg. Med. Chem. 7,
2905e2914.
Jo€els, M., Karst, H., 2012. Corticosteroid effects on calcium signaling in limbic
neurons. Cell Calcium 51, 277e283. http://dx.doi.org/10.1016/j.ceca.2011.11.002.
Jo€els, M., Sarabdjitsingh, R.A., Karst, H., 2012. Unraveling the time domains of
corticosteroid hormone inﬂuences on brain activity: rapid, slow, and chronic
modes. Pharmacol. Rev. 64, 901e938. http://dx.doi.org/10.1124/pr.112.005892.
Kaneko, T., Fujiyama, F., Hioki, H., 2002. Immunohistochemical localization of
candidates for vesicular glutamate transporters in the rat brain. J. Comp. Neurol.
444, 39e62.
Kawamura, Y., Fukaya, M., Maejima, T., Yoshida, T., Miura, E., Watanabe, M., Ohno-
Shosaku, T., Kano, M., 2006. The CB1 cannabinoid receptor is the major
cannabinoid receptor at excitatory presynaptic sites in the hippocampus and
cerebellum. J. Neurosci. 26, 2991e3001.
Karst, H., Berger, S., Turiault, M., Tronche, F., Schütz, G., Jo€els, M., 2005. Mineralo-
corticoid receptors are indispensable for nongenomic modulation of hippo-
campal glutamate transmission by corticosterone. Proc. Natl. Acad. Sci. U. S. A.
102, 19204e19207. http://dx.doi.org/10.1073/pnas.0507572102.
Keimpema, E., Alpar, A., Howell, F., Malenczyk, K., Hobbs, C., Hurd, Y.L.,
Watanabe, M., Sakimura, K., Kano, M., Doherty, P., Harkany, T., 2013. Diac-
ylglycerol lipase a manipulation reveals developmental roles for intercellular
endocannabinoid signaling. Sci. Rep. 3, 2093.
Kilkenny, C., Browne, W., Cuthill, I.C., Emerson, M., Altman, D.G., NC3Rs Reporting
Guidelines Working Group, 2010. Animal research: reporting in vivo experi-
ments: the ARRIVE guidelines. Br. J. Pharmacol. 160, 1577e1579. http://
dx.doi.org/10.1111/j.1476-5381.2010.00872.x.
Kim, J., Hoffman, D.A., 2008. Potassium channels: newly found players in synaptic
plasticity. Neuroscientist 14, 276e286. http://dx.doi.org/10.1177/
1073858408315041.
K€ofalvi, A., Fritzsche, M., 2008. The endocannabinoid system is a major player in
schizophrenia. In: K€ofalvi, A. (Ed.), Cannabinoids and the Brain. Springer, US,
pp. 485e528.
K€ofalvi, A., Pereira, M.F., Rebola, N., Rodrigues, R.J., Oliveira, C.R., Cunha, R.A., 2007.
Anandamide and NADA bi-directionally modulate presynaptic Ca2þ levels and
transmitter release in the hippocampus. Br. J. Pharmacol. 151, 551e563. http://
dx.doi.org/10.1038/sj.bjp.0707252.
K€ofalvi, A., Vizi, E.S., Ledent, C., Sperlagh, B., 2003. Cannabinoids inhibit the release
of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1
receptor-independent action. Eur. J. Neurosci. 18, 1973e1978.
Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J.F., Beslot, F., B€ohme, G.A.,
Imperato, A., Pedrazzini, T., Roques, B.P., Vassart, G., Fratta, W., Parmentier, M.,
1999. Unresponsiveness to cannabinoids and reduced addictive effects of opi-
ates in CB1 receptor knockout mice. Science 283, 401e404.
Maggio, N., Segal, M., 2012. Steroid modulation of hippocampal plasticity: switching
between cognitive and emotional memories. Front. Cell. Neurosci. 6, 12. http://
dx.doi.org/10.3389/fncel.2012.00012.
Manza, L.L., Stamer, S.L., Ham, A.J., Codreanu, S.G., Liebler, D.C., 2005. Sample
preparation and digestion for proteomic analyses using spin ﬁlters. Proteomics
5, 1742e1745.
Marsicano, G., Lutz, B., 1999. Expression of the cannabinoid receptor CB1 in distinct
neuronal subpopulations in the adult mouse forebrain. Eur. J. Neurosci. 11,
4213e4225.
Marsicano, G., Wotjak, C.T., Azad, S.C., Bisogno, T., Rammes, G., Cascio, M.G.,
Hermann, H., Tang, J., Hofmann, C., Zieglg€ansberger, W., Di Marzo, V., Lutz, B.,
2002. The endogenous cannabinoid system controls extinction of aversive
memories. Nature 418, 530e534. http://dx.doi.org/10.1038/nature00839.
Martens, H., Weston, M.C., Boulland, J.L., Gronborg, M., Grosche, J., Kacza, J.,
Hoffmann, A., Matteoli, M., Takamori, S., Harkany, T., Chaudhry, F.A.,
Rosenmund, C., Erck, C., Jahn, R., Hartig, W., 2008. Unique luminal localization of
VGAT-C terminus allows for selective labeling of active cortical GABAergic
synapses. J. Neurosci. 28, 13125e13131.
McGrath, J.C., Drummond, G.B., McLachlan, E.M., Kilkenny, C., Wainwright, C.L.,
2010. Guidelines for reporting experiments involving animals: the ARRIVE
guidelines. Br. J. Pharmacol. 160, 1573e1576. http://dx.doi.org/10.1111/j.1476-
5381.2010.00873.x.
Monory, K., Massa, F., Egertova, M., Eder, M., Blaudzun, H., Westenbroek, R.,
Kelsch, W., Jacob, W., Marsch, R., Ekker, M., Long, J., Rubenstein, J.L., Goebbels, S.,
Nave, K.A., During, M., Klugmann, M., W€olfel, B., Dodt, H.U., Zieglg€ansberger, W.,Wotjak, C.T., Mackie, K., Elphick, M.R., Marsicano, G., Lutz, B., 2006. The endo-
cannabinoid system controls key epileptogenic circuits in the hippocampus.
Neuron 51, 455e466.
Mora, F., Segovia, G., Del Arco, A., de Blas, M., Garrido, P., 2012. Stress, neuro-
transmitters, corticosterone and body-brain integration. Brain Res. 1476, 71e85.
http://dx.doi.org/10.1016/j.brainres.2011.12.049.
Morsink, M.C., Jo€els, M., Sarabdjitsingh, R.A., Meijer, O.C., De Kloet, E.R., Datson, N.A.,
2006. The dynamic pattern of glucocorticoid receptor-mediated transcriptional
responses in neuronal PC12 cells. J. Neurochem. 99, 1282e1298. http://
dx.doi.org/10.1111/j.1471-4159.2006.04187.x.
Murineddu, G., Lazzari, P., Ruiu, S., Sanna, A., Loriga, G., Manca, I., Falzoi, M., Dessì, C.,
Curzu, M.M., Chelucci, G., Pani, L., Pinna, G.A., 2006. Tricyclic pyrazoles. 4.
Synthesis and biological evaluation of analogues of the robust and selective CB2
cannabinoid ligand 1-(20 ,40-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-
dihydroindeno[1,2-c]pyrazole-3-carboxamide. J. Med. Chem. 49, 7502e7512.
http://dx.doi.org/10.1021/jm060920d.
Olijslagers, J.E., de Kloet, E.R., Elgersma, Y., van Woerden, G.M., Jo€els, M., Karst, H.,
2008. Rapid changes in hippocampal CA1 pyramidal cell function via pre- as
well as post-synaptic membrane mineralocorticoid receptors. Eur. J. Neurosci.
27, 2542e2550. http://dx.doi.org/10.1111/j.1460-9568.2008.06220.x.
Opris, I., Casanova, M.F., 2014. Prefrontal cortical minicolumn: from executive
control to disrupted cognitive processing. Brain 137, 1863e1875. http://
dx.doi.org/10.1093/brain/awt359.
Paxinos, G., Watson, C., 1998. The Rat Brain in Stereotaxic Coordinates. Academic
Press.
Pertwee, R.G., Howlett, A.C., Abood, M.E., Alexander, S.P., Di Marzo, V., Elphick, M.R.,
Greasley, P.J., Hansen, H.S., Kunos, G., Mackie, K., Mechoulam, R., Ross, R.A.,
2010. International Union of basic and clinical pharmacology. LXXIX. Cannabi-
noid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 62,
588e631. http://dx.doi.org/10.1124/pr.110.003004.
Phillips, G.R., Huang, J.K., Wang, Y., Tanaka, H., Shapiro, L., Zhang, W., Shan, W.S.,
Arndt, K., Frank, M., Gordon, R.E., Gawinowicz, M.A., Zhao, Y., Colman, D.R.,
2001. The presynaptic particle web: ultrastructure, composition, dissolution,
and reconstitution. Neuron 32, 63e77.
Popoli, M., Yan, Z., McEwen, B.S., Sanacora, G., 2011. The stressed synapse: the
impact of stress and glucocorticoids on glutamate transmission. Nat. Rev.
Neurosci. 13, 22e37. http://dx.doi.org/10.1038/nrn3138.
Raiteri, L., Raiteri, M., 2000. Synaptosomes still viable after 25 years of superfusion.
Neurochem. Res. 25, 1265e1274.
Rehm, H., Wiedenmann, B., Betz, H., 1986. Molecular characterization of synapto-
physin, a major calcium-binding protein of the synaptic vesicle membrane.
EMBO J. 5, 535e541.
Reisenberg, M., Singh, P.K., Williams, G., Doherty, P., 2012. The diacylglycerol li-
pases: structure, regulation and roles in and beyond endocannabinoid signal-
ling. Philos. Trans. R. Soc. Lond B Biol. Sci. 367, 3264e3275. http://dx.doi.org/
10.1098/rstb.2011.0387.
Sarabdjitsingh, R.A., Meijer, O.C., de Kloet, E.R., 2010. Speciﬁcity of glucocorticoid
receptor primary antibodies for analysis of receptor localization patterns in
cultured cells and rat hippocampus. Brain Res. 1331, 1e11. http://dx.doi.org/
10.1016/j.brainres.2010.03.052.
Schnell, S.A., Staines, W.A., Wessendorf, M.W., 1999. Reduction of lipofuscin-like
autoﬂuorescence in ﬂuorescently labeled tissue. J. Histochem. Cytochem 47,
719e730.
Sebastian, V., Estil, J.B., Chen, D., Schrott, L.M., Serrano, P.A., 2013. Acute physio-
logical stress promotes clustering of synaptic markers and alters spine
morphology in the hippocampus. PLoS One 8, e79077. http://dx.doi.org/
10.1371/journal.pone.0079077.
Treccani, G., Musazzi, L., Perego, C., Milanese, M., Nava, N., Bonifacino, T.,
Lamanna, J., Malgaroli, A., Drago, F., Racagni, G., Nyengaard, J.R., Wegener, G.,
Bonanno, G., Popoli, M., 2014. Stress and corticosterone increase the readily
releasable pool of glutamate vesicles in synaptic terminals of prefrontal and
frontal cortex. Mol. Psychiatry 19, 433e443. http://dx.doi.org/10.1038/
mp.2014.5.
Trezza, V., Campolongo, P., 2013. The endocannabinoid system as a possible target
to treat both the cognitive and emotional features of post-traumatic stress
disorder (PTSD). Front. Behav. Neurosci. 7, 100. http://dx.doi.org/10.3389/
fnbeh.2013.00100.
Tse, Y.C., Bagot, R.C., Hutter, J.A., Wong, A.S., Wong, T.P., 2011. Modulation of synaptic
plasticity by stress hormone associates with plastic alteration of synaptic NMDA
receptor in the adult hippocampus. PLoS One 6, e27215. http://dx.doi.org/
10.1371/journal.pone.0027215.
Tsou, K., Brown, S., Sa~nudo-Pe~na, M.C., Mackie, K., Walker, J.M., 1998. Immunohis-
tochemical distribution of cannabinoid CB1 receptors in the rat central nervous
system. Neuroscience 83, 393e411 doi.
Wang, C.-C., Wang, S.-J., 2009. Modulation of presynaptic glucocorticoid receptors
on glutamate release from rat hippocampal nerve terminals. Synap. N. Y. N 63,
745e751. http://dx.doi.org/10.1002/syn.20654.
Whittaker, V.P., Michaelson, I.A., Kirkland, R.J., 1964. The separation of synaptic
vesicles from nerve-ending particles (’synaptosomes'). Biochem. J. 90, 293e303.
Wisniewski, J.R., Zougman, A., Nagaraj, N., Mann, M., 2009. Universal sample
preparation method for proteome analysis. Nat. Methods 6, 359e362.
Yoshida, T., Fukaya, M., Uchigashima, M., Miura, E., Kamiya, H., Kano, M.,
Watanabe, M., 2006. Localization of diacylglycerol lipase-alpha around post-
synaptic spine suggests close proximity between production site of an endo-
cannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1
R.M. Bitencourt et al. / Neurochemistry International 90 (2015) 72e8484receptor. J. Neurosci. 26, 4740e4751.
Yu, S., Yang, S., Holsboer, F., Sousa, N., Almeida, O.F.X., 2011. Glucocorticoid regu-
lation of astrocytic fate and function. PLoS One 6, e22419. http://dx.doi.org/
10.1371/journal.pone.0022419.
Zaki, A., Barrett-Jolley, R., 2002. Rapid neuromodulation by cortisol in the rat par-
aventricular nucleus: an in vitro study. Br. J. Pharmacol. 137, 87e97. http://dx.doi.org/10.1038/sj.bjp.0704832.
Zhang, H.-Y., Bi, G.-H., Li, X., Li, J., Qu, H., Zhang, S.-J., Li, C.-Y., Onaivi, E.S.,
Gardner, E.L., Xi, Z.-X., Liu, Q.-R., 2015. Species differences in cannabinoid re-
ceptor 2 and receptor responses to cocaine self-administration in mice and rats.
Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 40,
1037e1051. http://dx.doi.org/10.1038/npp.2014.297.
